alphaveAJANTPHARM₹3,540.00

Ajanta Pharmaceuticals Ltd.

₹ CrorePeersALKEM IPCALAB TORNTPHARM ABBOTINDIA ANTHEM GLAXO MEDANTA GLENMARKMcap ₹44,374 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Returns
Return on Common Equity	22.90	24.28	23.33	23.33
Return on Assets	17.60	18.35	17.16	17.16
Return on Capital Employed	27.69	27.75	25.78	25.78
Return on Invested Capital	24.43	27.16	22.97	24.07
Margins
EBITDA Margin	27.85	27.10	25.58	25.40
Operating Margin	24.63	24.00	22.40	22.40
Incremental Operating Margin	—	17.95	13.21	—
Pretax Margin	26.47	25.58	25.26	25.85
Net Income Margin	19.39	19.80	19.37	19.65
Net Income to Common Margin	19.41	19.80	19.37	19.57
FCF Margin	15.03	18.06	3.01	3.01
Additional
Effective Tax Rate	26.73	22.60	23.35	24.00
Dvd Payout Ratio	78.68	37.96	33.12	—
Sustainable Growth Rate	4.88	15.06	15.60	23.33
Incremental Operating Margin %	17.95	13.21	21.35	—

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.